SC Pharmaceuticals fell over 6% to HKD 14.6, with a total market value of HKD 6.18 billion. The company announced after the market closed yesterday that, according to preliminary calculations by the finance department, it expects a net profit attributable to shareholders of the listed company to be negative for the fiscal year 2024, and the operating revenue after deductions to be below HKD 300 million. In accordance with the relevant provisions of the Shenzhen Stock Exchange's listing rules, the company's stock trading may be subject to delisting risk warnings after the disclosure of the 2024 annual report. This is the second risk warning regarding the potential delisting risk for the company's stock trading